The U.S. FDA approved Roche Holding's oral drug giredestrant (Wilserdly) in combination with everolimus on November 16, 2026, for advanced ER-positive, HER2-negative, ESR1-mutated breast cancer. In the phase III evERA trial, giredestrant reduced the risk of disease progression or death by 62%, extending median progression-free survival to 10.0 months. Roche is awaiting decisions for earlier disease stages, where giredestrant could become its top product.
Story comments
Loading comments…